Physician profile
Siddharth Mathur
NPI 1578728986
$104,759.23
in general payments reported to CMS, 2019-2025
40 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $2,149 · 2021: $993 · 2022: $1,734 · 2023: $1,456 · 2024: $77K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $13K · Food and Beverage: $9,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,110.00 |
| Travel and Lodging | $12,645.47 |
| Food and Beverage | $9,453.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $92,947.13 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,552.60 | 2019-2025 | |
| Boston Scientific Corporation | $1,516.59 | 2019-2025 | Exalt Model D, Watchman Flx |
| Endogastric Solutions, INC | $1,305.54 | 2020-2024 | Esophyx |
| Janssen Biotech, INC. | $1,015.05 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $769.38 | 2019-2025 | Xifaxan, Relistor |
| Ipsen Biopharmaceuticals, INC | $486.53 | 2024-2025 | Iqirvo |
| Celgene Corporation | $444.71 | 2019-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $441.38 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $378.55 | 2019-2025 | Rebyota |
| Medtronic, INC. | $347.17 | 2022-2024 | Endoflip, Pillcam, Nexpowder |
| Intercept Pharmaceuticals, INC. | $337.53 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $227.46 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $222.84 | 2020-2023 | |
| Pfizer INC. | $217.75 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $215.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $180.48 | 2019-2025 | |
| Lilly USA, LLC | $165.17 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $133.62 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $126.80 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $120.00 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $71.44 | 2023 | Fujifilm |
| Enterra Medical, INC. | $71.12 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $61.79 | 2022-2023 | Givlaari |
| Ardelyx, INC. | $56.44 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $45.60 | 2024-2025 | Dupixent |
| Lucid Diagnostics INC. | $37.48 | 2023 | |
| Exact Sciences Corporation | $36.67 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Organon LLC | $32.72 | 2023 | Hadlima, Renflexis |
| Ucb, INC. | $27.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $26.62 | 2020-2021 | |
| Allergan, INC. | $25.91 | 2019 | |
| Vivus LLC | $24.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.55 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $17.16 | 2019 | |
| Axonics, INC. | $15.60 | 2020 | |
| Redhill Biopharma INC. | $13.93 | 2020 | |
| Shionogi INC | $12.29 | 2019 | |
| Medtronic USA, INC. | $10.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.